Literature DB >> 11264478

Molecular basis of ethnic differences in drug disposition and response.

H G Xie1, R B Kim, A J Wood, C M Stein.   

Abstract

Ethnicity is an important demographic variable contributing to interindividual variability in drug metabolism and response. In this rapidly expanding research area many genetic factors that account for the effects of ethnicity on pharmacokinetics, pharmacodynamics, and drug safety have been identified. This review focuses on recent developments that have improved understanding of the molecular mechanisms responsible for such interethnic differences. Genetic variations that may provide a molecular basis for ethnic differences in drug metabolizing enzymes (CYP 2C9, 2C19, 2D6, and 3A4), drug transporter (P-glycoprotein), drug receptors (adrenoceptors), and other functionally important proteins (eNOS and G proteins) are discussed. A better understanding of the molecular basis underlying ethnic differences in drug metabolism, transport, and response will contribute to improved individualization of drug therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11264478     DOI: 10.1146/annurev.pharmtox.41.1.815

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  133 in total

Review 1.  Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment.

Authors:  Valentine J Burroughs; Randall W Maxey; Richard A Levy
Journal:  J Natl Med Assoc       Date:  2002-10       Impact factor: 1.798

2.  Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions.

Authors:  A L Beitelshees; R B Horenstein; M R Vesely; M R Mehra; A R Shuldiner
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

Review 3.  Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome.

Authors:  Michael Camilleri; David A Katzka
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-08       Impact factor: 4.052

4.  No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers.

Authors:  Linda C Johansson; Magnus Andersson; Gunnar Fager; David Gustafsson; Ulf G Eriksson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Inference from the relationships between linkage disequilibrium and allele frequency distributions of 240 candidate SNPs in 109 drug-related genes in four Asian populations.

Authors:  Pei-Chieng Cha; Ryo Yamada; Akihiro Sekine; Yusuke Nakamura; Chong-Lek Koh
Journal:  J Hum Genet       Date:  2004-09-11       Impact factor: 3.172

Review 6.  The role of pharmacogenetics in nonmalignant gastrointestinal diseases.

Authors:  Michael Camilleri
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-07       Impact factor: 46.802

7.  Call to action: cardiovascular disease in Asian Americans: a science advisory from the American Heart Association.

Authors:  Latha P Palaniappan; Maria Rosario G Araneta; Themistocles L Assimes; Elizabeth L Barrett-Connor; Mercedes R Carnethon; Michael H Criqui; Gordon L Fung; K M Venkat Narayan; Hamang Patel; Ruth E Taylor-Piliae; Peter W F Wilson; Nathan D Wong
Journal:  Circulation       Date:  2010-08-23       Impact factor: 29.690

Review 8.  Implications of pharmacogenetic testing for patients taking warfarin or clopidogrel.

Authors:  Megan M Donohue; David L Tirschwell
Journal:  Curr Neurol Neurosci Rep       Date:  2011-02       Impact factor: 5.081

Review 9.  The clinical pharmacokinetics of darifenacin.

Authors:  Andrej Skerjanec
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 10.  Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.

Authors:  Katarzyna Drozda; Daniel J Müller; Jeffrey R Bishop
Journal:  Pharmacotherapy       Date:  2014-02       Impact factor: 4.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.